Zeteo Biomedical today announced the ZEOx1 OrionMRQ nasal drug and vaccine delivery device. The device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.
Nasal administration provides needle free, rapid systemic uptake into the body via the nose. Nasal delivery of vaccines can invoke a fast local immune response in the respiratory track, which is frequently the primary route of infection for contagious pathogens such as pandemic flu or coronavirus. The ZEOx1 OrionMRQ device is intuitive to use, enabling either patient self-administration or administration by caregivers with configurations available for both adults and children.
The OrionMRQ reloadable nasal delivery device can store up to four unit doses in the on-board storage compartment. The device is compact making it easy to carry in a pocket or purse. Zeteo intranasal delivery devices incorporate novel packaging technology utilizing a Form Fill Seal (FFS) flexible foil, packaging the drug or vaccine in a unit dose blister reducing the cost and eliminating the supply chain constraints of glass vials.
ZEOx1 blister packaging provides barrier properties to protect the drug or vaccine during storage and transport and can be stored at room temperature, refrigerated or frozen storage conditions. The ZEOx1 packaging technology is commercially scalable to produce millions of doses per day; an important requirement for rapid, cost effective deployment of vaccines and medical countermeasures to global populations.
